JPMorgan Upgrades Recursion Pharmaceuticals to Overweight on FAP Treatment Prospects

JPMorgan upgraded Recursion Pharmaceuticals (RXRX) to Overweight from Neutral, raising the price target to $11. The upgrade follows promising clinical trials for the MEK 1/2 inhibitor REC-4881 in Familial Adenomatous Polyposis (FAP) treatment. Estimated peak sales for REC-4881 are over $1 billion, with the company also working on REC-617, a CDK7 inhibitor for platinum-resistant ovarian cancer. The positive clinical trials support Recursion's long-term prospects, with over $400 million in milestone payments from pharmaceutical partnerships.